| ［1］ |
WU Q, Dudley MZ, Chen X, et al. Evaluation of the safety profile of COVID⁃19 vaccines: a rapid review ［J］. BMC Med, 2021,19（1）:173. doi: 10.1186/s12916⁃021⁃02059⁃5.
|
| ［2］ |
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer⁃BioNTech COVID⁃19 Vaccine ⁃ United States, December 14⁃23, 2020［J］. MMWR Morb Mortal Wkly Rep, 2021,70（2）:46⁃51. doi: 10.15585/mmwr.mm7002e1.
|
| ［3］ |
Lee EJ, Cines DB, Gernsheimer T, et al. Thrombocytopenia following Pfizer and Moderna SARS⁃CoV⁃2 vaccination ［J］. Am J Hematol, 2021,96（5）:534⁃537.doi: 10.1002/ajh.26132.
|
| ［4］ |
Welsh KJ, Baumblatt J, Chege W, et al. Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID⁃19 vaccines reported to the Vaccine Adverse Event Reporting System （VAERS）［J］. Vaccine, 2021,39（25）:3329⁃3332. doi: 10.1016/j.vaccine.2021.04.054.
|
| ［5］ |
Bril F, Al Diffalha S, Dean M, et al. Autoimmune hepatitis developing after coronavirus disease 2019 （COVID⁃19） vaccine: Causality or casualty?［J］. J Hepatol, 2021,75（1）:222⁃224. doi: 10.1016/j.jhep.2021.04.003.
|
| ［6］ |
Ghielmetti M, Schaufelberger HD, Mieli⁃Vergani G, et al. Acute autoimmune⁃like hepatitis with atypical anti⁃mitochondrial antibody after mRNA COVID⁃19 vaccination: A novel clinical entity?［J］. J Autoimmun, 2021,123:102706. doi: 10.1016/j.jaut. 2021.102706.
|
| ［7］ |
Rela M, Jothimani D, Vij M, et al. Auto⁃immune hepatitis following COVID vaccination［J］. J Autoimmun, 2021,123:102688. doi: 10.1016/j.jaut.2021.102688.
|
| ［8］ |
Thongprasom K, Pengpis N, Phattarataratip E, et al. Oral pemphigus after COVID⁃19 vaccination［J］. Oral Dis, 2021. doi: 10.1111/odi.14034.
|
| ［9］ |
Koutlas IG, Camara R, Argyris PP, et al. Development of pemphigus vulgaris after the second dose of the mRNA⁃1273 SARS⁃Cov⁃2 vaccine［J］. Oral Dis, 2021. doi: 10.1111/odi.14089.
|
| ［10］ |
Tomayko MM, Damsky W, Fathy R, et al. Subepidermal blistering eruptions, including bullous pemphigoid, following COVID⁃19 vaccination ［J］. J Allergy Clin Immunol, 2021,148（3）:750⁃751. doi: 10.1016/j.jaci.2021.06.026.
|
| ［11］ |
Damiani G, Pacifico A, Pelloni F, et al. The first dose of COVID⁃19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?［J］. J Eur Acad Dermatol Venereol, 2021,35（10）:e645⁃e647. doi: 10.1111/jdv.17472.
|
| ［12］ |
Dell′Antonia M, Anedda S, Usai F, et al. Bullous pemphigoid triggered by COVID⁃19 vaccine: Rapid resolution with corticosteroid therapy［J］. Dermatol Ther, 2022,35（1）:e15208. doi: 10.1111/dth.15208.
|
| ［13］ |
Vojdani A, Kharrazian D. Potential antigenic cross⁃reactivity between SARS⁃CoV⁃2 and human tissue with a possible link to an increase in autoimmune diseases［J］. Clin Immunol, 2020,217:108480. doi: 10.1016/j.clim.2020.108480.
|
| ［14］ |
Amorim Dos Santos J, Normando A, Carvalho da Silva RL, et al. Oral mucosal lesions in a COVID⁃19 patient: New signs or secondary manifestations?［J］. Int J Infect Dis, 2020,97:326⁃328. doi: 10.1016/j.ijid.2020.06.012.
|
| ［15］ |
Perricone C, Colafrancesco S, Mazor RD, et al. Autoimmune/inflammatory syndrome induced by adjuvants （ASIA） 2013: Unveiling the pathogenic, clinical and diagnostic aspects［J］. J Autoimmun, 2013,47:1⁃16. doi: 10.1016/j.jaut.2013.10.004.
|
